Patent ID: 11912766
Assignee: ALLAKOS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 8:
9. The anti-Siglec-7 antibody of claim 1, wherein the variant Fc region is a human IgG1 region, human IgG2 region or human IgG4 region, wherein:
(a) the human IgG1 region comprises amino acid modifications:
(i) L234A and L235A;
(ii) A327G, A330S, and P331S;
(iii) E233P, L234V, L235A, and a deletion of G236;
(iv) E233P, L234V, and L235A;
(v) E233P, L234V, L235A, a deletion of G236, A327G, A330S, and P331S;
(vi) E233P, L234V, L235A, A327G, A330S, and P331S;
(vii) N297A, N297G, or N297Q;
(viii) L242C, N297C, and K334C;
(ix) A287C, N297G, and L306C;
(x) R292C, N297G, and V302C;
(xi) N297G, V323C, and I332C;
(xii) V259C, N297G, and L306C
(xiii) L234F, L235Q, K322Q, M252Y, S254T,and T256E; or
(xiv) L234A, L235A, and P329G;
(b) the human IgG2 regions comprises amino acid modifications:
(i) A330S and P331S;
(ii) V234A, G237A, P238S, H268A, V309L, A330S, and P331S; or
(iii) V234A, G237A, H268Q, V309L, A330S, P331S, C232S, C233S, S267E, L328F, M252Y, S254T, or T256E; and
(c) the human IgG4 region comprises amino acid modifications:
(i) E233P, F234V, L235A, and a deletion of G236;
(ii) E233P, F234V,and L235A; or
(iii) S228P and L235E/A.